File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Amlodipine, felodipine, and isradipine in the treatment of Chinese patients with mild-to-moderate hypertension

TitleAmlodipine, felodipine, and isradipine in the treatment of Chinese patients with mild-to-moderate hypertension
Authors
Issue Date1998
PublisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clinthera
Citation
Clinical Therapeutics, 1998, v. 20 n. 6, p. 1159-1169 How to Cite?
AbstractOptimal treatment of hypertension requires the use of effective antihypertensive drugs. Calcium channel blockers are widely used in the treatment of hypertension and appear to be particularly efficacious in ethnic Chinese patients. The aim of this open-label study was to prospectively investigate the efficacy and tolerability of three dihydropyridine calcium channel blockers in sequence, using the same protocol for each. After 2 weeks of placebo treatment, 73 males and 45 females (mean age, 45 ± 10 years; mean weight, 67 ± 10 kg) with essential hypertension (diastolic blood pressure, 95 to 115 mm Hg) were treated with amlodipine (n = 41), felodipine (n = 38), or isradipine (n = 39) for 8 weeks, with dose titration after 4 weeks. Mean seated systolic and diastolic blood pressure decreased by 23/17, 30/17, and 20/15 mm Hg after 8 weeks of treatment with amlodipine, felodipine, and isradipine, respectively. These reductions were all statistically significant. Blood pressure was controlled (defined as diastolic pressure <90 mm Hg at the final visit or a decrease from baseline of ≥ 10 mm Hg) in 85%, 74%, and 74% of patients receiving amlodipine, felodipine, and isradipine, respectively. There were no significant changes in heart rate, plasma lipid levels, or serum biochemistry markers with any of the three treatments. No serious adverse events occurred, but mild adverse effects, including headaches, flushing, tachycardia, dizziness, and edema, were reported; 1 (2%), 6 (16%), and 5 (13%) patients receiving amlodipine, felodipine, and isradipine, respectively, withdrew from the study (P < 0.05). The results of this study indicate that all three drugs are highly effective in lowering blood pressure and are well tolerated in Chinese patients with mild-to- moderate hypertension.
Persistent Identifierhttp://hdl.handle.net/10722/91571
ISSN
2015 Impact Factor: 2.925
2015 SCImago Journal Rankings: 0.997
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorWu, BZen_HK
dc.date.accessioned2010-09-17T10:21:33Z-
dc.date.available2010-09-17T10:21:33Z-
dc.date.issued1998en_HK
dc.identifier.citationClinical Therapeutics, 1998, v. 20 n. 6, p. 1159-1169en_HK
dc.identifier.issn0149-2918en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91571-
dc.description.abstractOptimal treatment of hypertension requires the use of effective antihypertensive drugs. Calcium channel blockers are widely used in the treatment of hypertension and appear to be particularly efficacious in ethnic Chinese patients. The aim of this open-label study was to prospectively investigate the efficacy and tolerability of three dihydropyridine calcium channel blockers in sequence, using the same protocol for each. After 2 weeks of placebo treatment, 73 males and 45 females (mean age, 45 ± 10 years; mean weight, 67 ± 10 kg) with essential hypertension (diastolic blood pressure, 95 to 115 mm Hg) were treated with amlodipine (n = 41), felodipine (n = 38), or isradipine (n = 39) for 8 weeks, with dose titration after 4 weeks. Mean seated systolic and diastolic blood pressure decreased by 23/17, 30/17, and 20/15 mm Hg after 8 weeks of treatment with amlodipine, felodipine, and isradipine, respectively. These reductions were all statistically significant. Blood pressure was controlled (defined as diastolic pressure <90 mm Hg at the final visit or a decrease from baseline of ≥ 10 mm Hg) in 85%, 74%, and 74% of patients receiving amlodipine, felodipine, and isradipine, respectively. There were no significant changes in heart rate, plasma lipid levels, or serum biochemistry markers with any of the three treatments. No serious adverse events occurred, but mild adverse effects, including headaches, flushing, tachycardia, dizziness, and edema, were reported; 1 (2%), 6 (16%), and 5 (13%) patients receiving amlodipine, felodipine, and isradipine, respectively, withdrew from the study (P < 0.05). The results of this study indicate that all three drugs are highly effective in lowering blood pressure and are well tolerated in Chinese patients with mild-to- moderate hypertension.en_HK
dc.languageengen_HK
dc.publisherExcerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/clintheraen_HK
dc.relation.ispartofClinical Therapeuticsen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAmlodipine - adverse effects - therapeutic useen_HK
dc.subject.meshAntihypertensive Agents - adverse effects - therapeutic useen_HK
dc.subject.meshBlood Pressure - drug effectsen_HK
dc.subject.meshCalcium Channel Blockers - adverse effects - therapeutic useen_HK
dc.subject.meshFelodipine - adverse effects - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshHypertension - drug therapy - physiopathologyen_HK
dc.subject.meshIsradipine - adverse effects - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshProspective Studiesen_HK
dc.titleAmlodipine, felodipine, and isradipine in the treatment of Chinese patients with mild-to-moderate hypertensionen_HK
dc.typeArticleen_HK
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0149-2918(98)80111-2en_HK
dc.identifier.pmid9916609-
dc.identifier.scopuseid_2-s2.0-0032418198en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032418198&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume20en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1159en_HK
dc.identifier.epage1169en_HK
dc.identifier.isiWOS:000077985500010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.scopusauthoridLau, CP=35275317200en_HK
dc.identifier.scopusauthoridWu, BZ=7403590990en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats